Overview

Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

Status:
Completed
Trial end date:
2020-06-23
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
BRIM Biotechnology Inc.
Collaborator:
ORA, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions